MRI to Predict Outcomes of PDAC

Summary

This study focuses on patients who are receiving care for non-metastatic pancreatic cancer at Cedars-Sinai. The purpose of the study is to evaluate the role of a method of magnetic resonance imaging (MRI) analysis for individuals with pancreatic ductal adenocarcinoma (PDAC). Researchers aim to determine whether their newly developed, six-dimensional magnetic resonance imaging (6D-MRI) is effective in predicting outcomes to therapy in PDAC patients. 6D-MRI is a type of image analysis that can visualize high-resolution images of the pancreas and pancreatic tumors taken during MRI scans. These non-standard imaging techniques are for research purposes only. Participants will be asked to undergo 3 separate 6D-MRI procedures during the course of their cancer treatment. 6D-MRI provides a more complex analysis of images generated during the MRI than images from a standard MRI; there are no procedural differences between 6D-MRI and standard MRI. Participants should not expect to benefit from taking part in this study. Researchers hope to learn whether specific findings in the 6D-MRI can help select the best therapy for other patients in the future with the result of improving outcome.


Inclusion Criteria

  • Pancreatic cancer patients (with resectable or borderline resectable or locally advanced tumors) who will undergo neoadjuvant chemotherapy
  • Patients able to undergo at least two sets of MRI sessions
  • Access to a device that has the capability to sync to the Fitbit (or access to a family member's, caregiver's, or friend's device)
Show more

Study Location(s)

Cedars-Sinai Cancer at SOCC

More about this Clinical Trial

Full Title

IIT2020-12-PANDOL-PDAC : MRI Imaging to Predict Outcomes of Treatment in PDAC Patients

Details
Disease Type/Condition

Pancreatic Biliary Diseases, Pancreatic Cancer

Principal Investigator

Pandol, Stephen

Co-Investigators

Andrew Hendifar, Arsen Osipov, Debiao Li, Edwin Posadas, Marcio A Diniz, Nicholas Nissen, Qiang Wang, Simon Lo, Srinivas Gaddam

Age Group

Adult

Phase

N/A (Cancer Control) (Cancer Prevention)

IRB Number

STUDY00000573

ClinicalTrials.gov ID

NCT04700488

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Pancreatic Biliary Diseases, Pancreatic Cancer

Principal Investigator

Pandol, Stephen

Age Group

Adult

Phase

N/A (Cancer Control) (Cancer Prevention)

IRB Number

IIT2020-12-PANDOL-PDAC

ClinicalTrials.gov ID

NCT04700488

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?